CORDIS
EU research results

CORDIS

English EN

Improving Design, Evaluation and Analysis of early drug development Studies

Project information

Grant agreement ID: 633567

  • Start date

    1 January 2015

  • End date

    31 December 2018

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 108 939,48

  • EU contribution

    € 3 108 939,48

Coordinated by:

UNIVERSITY OF LANCASTER

United Kingdom

Objective

Drug development is a long and costly process which suffers from the major shortcoming that frequently failure is often only
determined during the final stage. Recently, it has been recognised that more care needs to be taken during the early stages
of development to avoid going into lengthy and costly confirmatory studies with ineffective or harmful treatments. To achieve
this goal it is essential to implement efficient methods for the design and analysis of such early development studies. The
expertise in this area is, however, limited at the moment and adequate methodology is only partially available. Using a
cross-sectorial, transnational approach, the IDEAS network brings together leading public and private sector researchers in
the field with ample experience in training to educate, promote and support the future leaders in medical statistics in general
and in the design and analysis of early developmental studies in particular.

Within the network, cross-sectorial, transnational teams will support young researchers with individual methodological
projects and devise an individually tailored training programme for them. Clinical advisors supplement the input of the
supervisory team and ensure practical relevance and uptake of the methods devised. The training activities are comprised of
a well-rounded mix of specialist, methodological components and generic, transferable skills. A mandatory set of networkwide
training activities is supplemented by individual training components and cross-sectorial secondments, and particular
attention is given to interaction and collaboration between researchers and supervisors across public and private sector
partners. At the end of their training the researchers will be uniquely qualified with expertise in the field, benefit from
experience in both public and private sector and can rely on a wide network of experts in the field in the future.

Coordinator

UNIVERSITY OF LANCASTER

Address

Bailrigg
La1 4yw Lancaster

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 819 863,64

Participants (7)

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 511 868,16

POLITECNICO DI TORINO

Italy

EU Contribution

€ 516 122,64

INSTITUT CURIE

France

Bayer Pharma AG

Germany

EU Contribution

€ 249 216,48

UNIVERSITAET BREMEN

Germany

EU Contribution

€ 498 432,96

JANSSEN PHARMACEUTICA NV

Belgium

EU Contribution

€ 250 560

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 262 875,60

Partners (2)

Aptiv Solutions

Germany

Clinical Trials Consulting & Training Limited

United Kingdom

Project information

Grant agreement ID: 633567

  • Start date

    1 January 2015

  • End date

    31 December 2018

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 108 939,48

  • EU contribution

    € 3 108 939,48

Coordinated by:

UNIVERSITY OF LANCASTER

United Kingdom